Pure Global: Europe's MedTech & The Post-Market Surprise

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

Pure Global: Europe's MedTech & The Post-Market Surprise

Ascolta gratuitamente

Vedi i dettagli del titolo

3 mesi a soli 0,99 €/mese

Dopo 3 mesi, 9,99 €/mese. Si applicano termini e condizioni.

A proposito di questo titolo

Many MedTech companies breathe a sigh of relief after achieving their European CE mark, believing the hardest part is over. But a recent guidance document from the EU's Medical Device Coordination Group (MDCG) on post-market surveillance is proving that the finish line has moved. This new interpretation demands a more dynamic and data-intensive approach to monitoring devices, catching many manufacturers off-guard. In this episode, we break down what this enhanced scrutiny really means for your business. We go beyond the regulatory jargon to reveal the hidden operational and financial burdens of these updated expectations, and discuss how proactive compliance is the only way to safeguard your hard-won market access in the EU. Imagine this: Your company's innovative cardiovascular device has been successful in the EU for two years. Suddenly, a routine audit flags your post-market data collection as non-compliant with the new MDCG guidance. You now have 90 days to implement a costly new patient follow-up study and overhaul your reporting system, or face the risk of having your CE certificate suspended right as you're planning your expansion. What You'll Learn: - What is the single biggest mistake companies make in their post-market surveillance plans? - How does the new MDCG guidance change the requirements for your Periodic Safety Update Report (PSUR)? - Why might your current clinical data be insufficient for the new Post-Market Clinical Follow-up (PMCF) standards? - What are the early warning signs that your PMS system is falling behind the new expectations? - How can you turn mandatory surveillance activities into a source of competitive advantage? - Is your designated Person Responsible for Regulatory Compliance (PRRC) truly prepared for these new demands? - What technology can help automate the intensified data collection and reporting? Contact us at info@pureglobal.com or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.

Ancora nessuna recensione